Pemigatinib for Bladder Cancer

Recruiting at5 trial locations

Overseen by Noah M Hahn, MD

Age: 18+

Sex: Any

Travel: May Be Covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Recruiting

Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Must not be taking: Chemotherapy, Immunotherapy, Monoclonal antibodies, others

Disqualifiers: Upper urinary tract cancer, High-grade urothelial carcinoma, Active second malignancy, others

No Placebo Group

Prior Safety Data

Breakthrough Therapy

Approved in 1 Jurisdiction

Trial Summary

What is the purpose of this trial?

This trial tests how well Pemigatinib, a pill that blocks proteins helping cancer grow, works in patients with bladder cancer that has come back after previous treatment. The drug aims to stop specific proteins needed for cancer growth.

Will I have to stop taking my current medications?

The trial information does not specify if you need to stop taking your current medications. However, if you have recently received anti-cancer therapy, radiotherapy, or undergone major surgery, you may need to wait 4 weeks before starting the study drug.

What data supports the effectiveness of the drug Pemigatinib for bladder cancer?

Research shows that Pemigatinib, a drug that targets specific genetic changes in cancer cells, has shown antitumor activity in patients with advanced bladder cancer that has certain genetic alterations. This suggests it could be effective for treating bladder cancer with these specific genetic changes. ^{1 2 3 4 5}

Is pemigatinib safe for humans?

Pemigatinib has been studied for safety in a phase 2 trial for bladder cancer with specific genetic changes, showing it is generally safe for humans, though like all medications, it may have side effects. ^{1 2 3 6 7}

What makes the drug Pemigatinib unique for treating bladder cancer?

Pemigatinib is unique because it specifically targets and inhibits fibroblast growth factor receptors (FGFR1-3), which are often altered in bladder cancer, making it a targeted therapy for tumors with these genetic changes. ^{1 2 3 8 9}

Research Team

Noah M Hahn, MD

Principal Investigator

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Eligibility Criteria

This trial is for adults over 18 with recurrent non-muscle invasive bladder cancer that was previously low- or intermediate-risk. They must be able to perform daily activities with little to no assistance (ECOG status 0-2) and have certain lab values within specific ranges. People can't join if they've had recent radiotherapy, surgery, or other cancer treatments, have high-grade urothelial carcinoma in their latest urine test, another active cancer besides some exceptions, or previous treatment with similar drugs.

Inclusion Criteria

Your test results must be within certain ranges.

Patients who give a written informed consent obtained according to local guidelines

My bladder cancer is confirmed to be at a low or intermediate risk and has not invaded the muscle.

Exclusion Criteria

I received my last cancer treatment less than 4 weeks ago or am still experiencing side effects.

I haven't had major surgery or significant injury in the last 4 weeks, or minor procedures in the last week.

I have been treated with specific drugs targeting fibroblast growth factor receptors.

Trial Timeline

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Treatment

Participants receive pemigatinib for 4-6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT)

4-6 weeks

Follow-up

Participants are monitored for safety and effectiveness after treatment, including assessment of complete response rate and relapse-free survival

24 months

Treatment Details

Interventions

• Pemigatinib (Inhibitor)

Trial Overview The study tests Pemigatinib's effectiveness on patients with recurring bladder tumors who've had prior low- or intermediate-risk cancers. It's taken orally for 4-6 weeks before the standard tumor removal surgery (TURBT).

Participant Groups

Group I: Treatment: Pemigatinib Experimental Treatment 1 Intervention

Patients will receive pemigatinib for 4 to 6 weeks prior to standard of care transurethral resection of bladder tumor (TURBT).

Who Is Running the Clinical Trial?

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Lead Sponsor

Trials

578

Recruited

33,600+

Dr. William G. Nelson

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Director since 1992

MD, PhD

Dr. Elizabeth Jaffee

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Chief Medical Officer since 2023

MD

Incyte Corporation

Industry Sponsor

Trials

408

Recruited

66,800+

Steven Stein

Incyte Corporation

Chief Medical Officer since 2015

MD from University of Witwatersrand

Hervé Hoppenot

Incyte Corporation

Chief Executive Officer since 2014

MBA from ESSEC Business School

Findings from Research

In a phase II study involving 260 patients with unresectable or metastatic urothelial carcinoma (UC) and FGFR3 alterations, pemigatinib showed clinical activity with overall response rates of 17.8% and 23.3% for different dosing schedules.

Pemigatinib was generally well tolerated, with common side effects including diarrhea and alopecia, and it demonstrated a median duration of response of about 6.2 months, indicating its potential as a treatment option for this patient population.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pemigatinib for Metastatic or Surgically Unresectable Urothelial Carcinoma With FGF/FGFR Genomic Alterations: Final Results From FIGHT-201. Necchi, A., Pouessel, D., Leibowitz, R., et al.[2023]

The combination of intravesical Bacillus Calmette-Guérin (BCG) and systemic pembrolizumab was found to be safe in a phase I trial involving 18 patients with high-grade non-muscle-invasive bladder cancer, with 69% of treated patients showing no evidence of disease after 3 months.

Despite some treatment-related adverse events, including one severe case of adrenal insufficiency and several grade 3 adverse events, the overall safety profile supports further investigation, leading to the initiation of a phase III trial to evaluate the efficacy of this combination.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment. Alanee, S., Sana, S., El-Zawahry, A., et al.[2022]

The cuproptosis-associated 11 gene signature (CuAGS-11) model can effectively predict overall survival (OS) and progression-free survival (PFS) in bladder cancer patients, helping to stratify them into high- and low-risk groups based on their response to treatments like Bacillus Calmette-Guerin (BCG) and immune checkpoint inhibitors (ICIs).

Patients in the high-risk group showed significantly lower response rates to BCG and higher recurrence rates, while those in the low-risk group experienced much better outcomes, suggesting that the CuAGS-11 model can guide personalized treatment strategies and potentially reduce the need for invasive monitoring procedures.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma. Yuan, H., Xiu, Y., Liu, T., et al.[2023]

Pembrolizumab, a checkpoint inhibitor, has been shown to significantly improve overall survival in patients with locally advanced or metastatic urothelial carcinoma who have progressed after cisplatin-containing chemotherapy, compared to standard chemotherapy options.

Additionally, evidence from Phase 1 and 2 trials suggests that checkpoint inhibitors like pembrolizumab are effective as a first-line treatment for patients who cannot tolerate cisplatin-based therapies.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pembrolizumab for the treatment of bladder cancer. Sundahl, N., Rottey, S., De Maeseneer, D., et al.[2018]

In a Phase 1 safety study involving six patients with non-muscle-invasive bladder cancer (NMIBC), intravesical administration of pembrolizumab was well tolerated, with no dose-limiting toxicities observed during dose escalation.

The treatment resulted in low-grade adverse events such as dysuria and fatigue, and importantly, there was no evidence of systemic absorption or immune effects, suggesting a localized action of the drug.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer. Woodcock, VK., Chen, JL., Purshouse, K., et al.[2023]

Pembrolizumab, an immunotherapy for advanced bladder cancer, led to significant tumor shrinkage after just one injection, demonstrating its efficacy in treating this type of cancer.

The patient experienced immune-related adverse events, specifically myasthenia gravis and myocarditis, which were effectively managed with early corticosteroid treatment, highlighting the importance of monitoring and addressing side effects in immunotherapy.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer. Todo, M., Kaneko, G., Shirotake, S., et al.[2022]

In a phase I trial involving 12 Chinese patients with advanced solid tumors, pemigatinib showed acceptable safety and tolerability, with 25% of patients experiencing grade 3 or higher adverse events.

The drug demonstrated preliminary efficacy, with partial responses observed in two patients with specific FGFR mutations, indicating its potential as a targeted therapy for tumors with FGF/FGFR alterations.

NCBI (Pubmed)

pubmed.ncbi.nlm.nih.gov

Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial. Deng, T., Zhang, L., Shi, Y., et al.[2023]

References

1. England pubmed.ncbi.nlm.nih.gov

Pemigatinib for Metastatic or Surgically Unresectable Urothelial Carcinoma With FGF/FGFR Genomic Alterations: Final Results From FIGHT-201. [2023]

2. Germany pubmed.ncbi.nlm.nih.gov

Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment. [2022]

3. England pubmed.ncbi.nlm.nih.gov

Targeting FGFRs by pemigatinib induces G1 phase cell cycle arrest, cellular stress and upregulation of tumor suppressor microRNAs. [2023]

4. Switzerland pubmed.ncbi.nlm.nih.gov

The cuproptosis-associated 11 gene signature as a predictor for outcomes and response to Bacillus Calmette-Guerin and immune checkpoint inhibitor therapies in bladder carcinoma. [2023]

5. England pubmed.ncbi.nlm.nih.gov

Pembrolizumab for the treatment of bladder cancer. [2018]

6. United States pubmed.ncbi.nlm.nih.gov

PemBla: A Phase 1 study of intravesical pembrolizumab in recurrent non-muscle-invasive bladder cancer. [2023]

7. Australia pubmed.ncbi.nlm.nih.gov

Pembrolizumab-induced myasthenia gravis with myositis and presumable myocarditis in a patient with bladder cancer. [2022]

8. England pubmed.ncbi.nlm.nih.gov

A drug safety evaluation of pemigatinib for advanced cholangiocarcinoma. [2023]

9. United States pubmed.ncbi.nlm.nih.gov

Pharmacokinetics, pharmacodynamics and efficacy of pemigatinib (a selective inhibitor of fibroblast growth factor receptor 1-3) monotherapy in Chinese patients with advanced solid tumors: a phase i clinical trial. [2023]